196 related articles for article (PubMed ID: 19291787)
1. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
Lok AS; Everhart JE; Chung RT; Kim HY; Everson GT; Hoefs JC; Greenson JK; Sterling RK; Lindsay KL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Ghany MG; Morishima C;
Hepatology; 2009 Jun; 49(6):1828-37. PubMed ID: 19291787
[TBL] [Abstract][Full Text] [Related]
2. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Lok AS; Everhart JE; Chung RT; Padmanabhan L; Greenson JK; Shiffman ML; Everson GT; Lindsay KL; Bonkovsky HL; Di Bisceglie AM; Lee WM; Morgan TR; Ghany MG; Morishima C;
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):245-54. PubMed ID: 17296533
[TBL] [Abstract][Full Text] [Related]
3. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
[TBL] [Abstract][Full Text] [Related]
4. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
Morishima C; Shiffman ML; Dienstag JL; Lindsay KL; Szabo G; Everson GT; Lok AS; Di Bisceglie AM; Ghany MG; Naishadham D; Morgan TR; Wright EC;
Am J Gastroenterol; 2012 Sep; 107(9):1388-98. PubMed ID: 22688849
[TBL] [Abstract][Full Text] [Related]
5. Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters.
Crisan D; Grigorescu M; Crisan N; Craciun R; Lupsor M; Radu C; Grigorescu MD; Suciu A; Epure F; Avram L; Leach N
J Physiol Pharmacol; 2019 Aug; 70(4):. PubMed ID: 31642820
[TBL] [Abstract][Full Text] [Related]
6. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
7. Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients.
Nirei K; Matsumura H; Kumakawa M; Matsumoto N; Nakamura H; Yamagami H; Matsuoka S; Moriyama M
Int J Med Sci; 2017; 14(1):45-52. PubMed ID: 28138308
[No Abstract] [Full Text] [Related]
8. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
Fontana RJ; Litman HJ; Dienstag JL; Bonkovsky HL; Su G; Sterling RK; Lok AS;
Liver Int; 2012 Apr; 32(4):665-74. PubMed ID: 22103814
[TBL] [Abstract][Full Text] [Related]
9. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.
Stättermayer AF; Rutter K; Beinhardt S; Wrba F; Scherzer TM; Strasser M; Hofer H; Steindl-Munda P; Trauner M; Ferenci P
Liver Int; 2014 Mar; 34(3):388-95. PubMed ID: 23870067
[TBL] [Abstract][Full Text] [Related]
10. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
Everson GT; Hoefs JC; Seeff LB; Bonkovsky HL; Naishadham D; Shiffman ML; Kahn JA; Lok AS; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Morishima C;
Hepatology; 2006 Dec; 44(6):1675-84. PubMed ID: 17133499
[TBL] [Abstract][Full Text] [Related]
11. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
Hung CH; Kuo FY; Wang JH; Lu SN; Hu TH; Chen CH; Lee CM; Eng HL
Antivir Ther; 2006; 11(4):483-9. PubMed ID: 16856622
[TBL] [Abstract][Full Text] [Related]
12. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
13. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
Freedman ND; Everhart JE; Lindsay KL; Ghany MG; Curto TM; Shiffman ML; Lee WM; Lok AS; Di Bisceglie AM; Bonkovsky HL; Hoefs JC; Dienstag JL; Morishima C; Abnet CC; Sinha R;
Hepatology; 2009 Nov; 50(5):1360-9. PubMed ID: 19676128
[TBL] [Abstract][Full Text] [Related]
14. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
Shiffman ML; Morishima C; Dienstag JL; Lindsay KL; Hoefs JC; Lee WM; Wright EC; Naishadham D; Everson GT; Lok AS; Di Bisceglie AM; Bonkovsky HL; Ghany MG;
Gastroenterology; 2009 Dec; 137(6):1986-94. PubMed ID: 19747918
[TBL] [Abstract][Full Text] [Related]
15. Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
Dultz G; Seelhof M; Herrmann E; Welker MW; Friedrich-Rust M; Teuber G; Kronenberger B; von Wagner M; Vermehren J; Sarrazin C; Zeuzem S; Hofmann WP
PLoS One; 2013; 8(8):e71262. PubMed ID: 23936497
[TBL] [Abstract][Full Text] [Related]
16. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
17. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
Fontana RJ; Dienstag JL; Bonkovsky HL; Sterling RK; Naishadham D; Goodman ZD; Lok AS; Wright EC; Su GL;
Gut; 2010 Oct; 59(10):1401-9. PubMed ID: 20675691
[TBL] [Abstract][Full Text] [Related]
18. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
[TBL] [Abstract][Full Text] [Related]
19. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels.
Iwasa M; Hara N; Miyachi H; Tanaka H; Takeo M; Fujita N; Kobayashi Y; Kojima Y; Kaito M; Takei Y
J Viral Hepat; 2009 Oct; 16(10):716-23. PubMed ID: 19302338
[TBL] [Abstract][Full Text] [Related]
20. Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary.
Werling K; Schaff Z; Dinya E; Tulassay Z
Pathol Oncol Res; 2010 Jun; 16(2):149-57. PubMed ID: 19757200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
